Qubit Pharmaceuticals is a French-American deeptech startup, focusing on discovering novel molecules for complex targets in healthcare and materials science. We leverage proprietary molecular simulation and quantum-physics based modeling technology to develop our own discovery programs that we either co-develop with or license out to pharmaceutical and industrial partners. This enables us to design more effective and safer drug candidates, aiming to significantly reduce the time and investment needed for discovery. In just 18 months, Qubit Pharmaceuticals grew its portfolio to 7 programs in oncology, immunology & antivirals.
Our cutting-edge technology is based on over 30 years of research by our academic founders, and relies on three main components: in-depth expertise in computational science and high-performance computing (HPC), quantum chemistry and artificial intelligence algorithms, and a powerful, automated cloud platform for molecular simulation with chemical accuracy. We recently announced the launch of the world's most powerful AI foundation model for molecular simulation.
Qubit Pharmaceuticals is looking for a Head of Quantum Computing for Chemistry (M/F) to manage a multidisciplinary team to develop quantum computing software and quantum applications for chemistry.

Qubit Pharmaceuticals brings unparalleled accuracy and precision to drug discovery and design, using quantum physics to develop life-changing treatments for major diseases.
We leverage our technologies and expertise to advance 7 fully owned drug discovery programs focusing on cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases. We also co-develop programs with academia and pharmaceutical partners.
Our proprietary ATLAS drug discovery platform unites our technologies based on 30 years of research from renowned scientists and founders, Louis Lagardère (Sorbonne University and CNRS), Matthieu Montes (CNAM), Jean-Philip Piquemal (Sorbonne University and CNRS), Jay Ponder (Washington University in St Louis), Pengyu Ren (University of Texas at Austin).
Their multidisciplinary team of 60 experts, led by CEO Robert Marino, works from Paris, France, Boston, USA - with a team based in Chicago, USA.